{"title":"西马鲁肽及其竞争性类似物治疗肥胖症的研究综述","authors":"Nahid Rao, Reenoo Jauhari, Vaishali Sati, Pallavi Godiyal","doi":"10.31069/japsr.v5i2.02","DOIUrl":null,"url":null,"abstract":"Obesity is a major public health problem in the world. This growing rate represents an epidemic that requires immediate attention. Oral Semaglutide is a semaglutide compound with an absorption enhancer, a sodium N- (8 - [2-hydroxybenzoyl] amino) caprylate (SNAC). The mechanism of action simply produces Glucagon-like peptide-1 (GLP-1) as a food-based digestive hormone that acts as an appetite signal, stimulates insulin release, inhibits glucagon production, and regulates diarrhea. This article shows the correlation of GLP-1 association with motivation to feed and Semaglutide’s anorectic effect and relation to cravings. We have performed complete searches from PubMed, Cochrane, Scopus, Medline, Medscape, and Wiley online library from 2015 to 2022. The trial data (SUSTAIN, PIONEER, STEP) suggested a major decrease in weight and HbA 1c. SELECT trial data showed cardiovascular safety of semaglutide over other anti-diabetic drugs. This review article summarized semaglutide trial data as an anti-obesity drug and compared the effects of semaglutide (oral and subcutaneous) with other GLP-1 analogs.","PeriodicalId":13749,"journal":{"name":"INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE\",\"authors\":\"Nahid Rao, Reenoo Jauhari, Vaishali Sati, Pallavi Godiyal\",\"doi\":\"10.31069/japsr.v5i2.02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Obesity is a major public health problem in the world. This growing rate represents an epidemic that requires immediate attention. Oral Semaglutide is a semaglutide compound with an absorption enhancer, a sodium N- (8 - [2-hydroxybenzoyl] amino) caprylate (SNAC). The mechanism of action simply produces Glucagon-like peptide-1 (GLP-1) as a food-based digestive hormone that acts as an appetite signal, stimulates insulin release, inhibits glucagon production, and regulates diarrhea. This article shows the correlation of GLP-1 association with motivation to feed and Semaglutide’s anorectic effect and relation to cravings. We have performed complete searches from PubMed, Cochrane, Scopus, Medline, Medscape, and Wiley online library from 2015 to 2022. The trial data (SUSTAIN, PIONEER, STEP) suggested a major decrease in weight and HbA 1c. SELECT trial data showed cardiovascular safety of semaglutide over other anti-diabetic drugs. This review article summarized semaglutide trial data as an anti-obesity drug and compared the effects of semaglutide (oral and subcutaneous) with other GLP-1 analogs.\",\"PeriodicalId\":13749,\"journal\":{\"name\":\"INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31069/japsr.v5i2.02\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31069/japsr.v5i2.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE
Obesity is a major public health problem in the world. This growing rate represents an epidemic that requires immediate attention. Oral Semaglutide is a semaglutide compound with an absorption enhancer, a sodium N- (8 - [2-hydroxybenzoyl] amino) caprylate (SNAC). The mechanism of action simply produces Glucagon-like peptide-1 (GLP-1) as a food-based digestive hormone that acts as an appetite signal, stimulates insulin release, inhibits glucagon production, and regulates diarrhea. This article shows the correlation of GLP-1 association with motivation to feed and Semaglutide’s anorectic effect and relation to cravings. We have performed complete searches from PubMed, Cochrane, Scopus, Medline, Medscape, and Wiley online library from 2015 to 2022. The trial data (SUSTAIN, PIONEER, STEP) suggested a major decrease in weight and HbA 1c. SELECT trial data showed cardiovascular safety of semaglutide over other anti-diabetic drugs. This review article summarized semaglutide trial data as an anti-obesity drug and compared the effects of semaglutide (oral and subcutaneous) with other GLP-1 analogs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
